SCYX
Price
$1.07
Change
-$0.00 (-0.00%)
Updated
Sep 26 closing price
Capitalization
45.07M
38 days until earnings call
TXMD
Price
$1.07
Change
+$0.01 (+0.94%)
Updated
Sep 26 closing price
Capitalization
12.38M
50 days until earnings call
Interact to see
Advertisement

SCYX vs TXMD

Header iconSCYX vs TXMD Comparison
Open Charts SCYX vs TXMDBanner chart's image
SCYNEXIS
Price$1.07
Change-$0.00 (-0.00%)
Volume$194.32K
Capitalization45.07M
TherapeuticsMD
Price$1.07
Change+$0.01 (+0.94%)
Volume$14.98K
Capitalization12.38M
SCYX vs TXMD Comparison Chart in %
Loading...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TXMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SCYX vs. TXMD commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCYX is a Hold and TXMD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (SCYX: $1.08 vs. TXMD: $1.07)
Brand notoriety: SCYX and TXMD are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: SCYX: 80% vs. TXMD: 85%
Market capitalization -- SCYX: $45.07M vs. TXMD: $12.38M
SCYX [@Pharmaceuticals: Generic] is valued at $45.07M. TXMD’s [@Pharmaceuticals: Generic] market capitalization is $12.38M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCYX’s FA Score shows that 0 FA rating(s) are green whileTXMD’s FA Score has 0 green FA rating(s).

  • SCYX’s FA Score: 0 green, 5 red.
  • TXMD’s FA Score: 0 green, 5 red.
According to our system of comparison, SCYX is a better buy in the long-term than TXMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCYX’s TA Score shows that 2 TA indicator(s) are bullish while TXMD’s TA Score has 3 bullish TA indicator(s).

  • SCYX’s TA Score: 2 bullish, 6 bearish.
  • TXMD’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, TXMD is a better buy in the short-term than SCYX.

Price Growth

SCYX (@Pharmaceuticals: Generic) experienced а -4.02% price change this week, while TXMD (@Pharmaceuticals: Generic) price change was -1.83% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

SCYX is expected to report earnings on Nov 05, 2025.

TXMD is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SCYX($45.1M) has a higher market cap than TXMD($12.4M). TXMD YTD gains are higher at: 24.419 vs. SCYX (-11.157). TXMD has higher annual earnings (EBITDA): -1.37M vs. SCYX (-19.29M). SCYX has more cash in the bank: 44.8M vs. TXMD (6.07M). SCYX has less debt than TXMD: SCYX (2.39M) vs TXMD (6.6M). SCYX has higher revenues than TXMD: SCYX (3.26M) vs TXMD (2.56M).
SCYXTXMDSCYX / TXMD
Capitalization45.1M12.4M364%
EBITDA-19.29M-1.37M1,408%
Gain YTD-11.15724.419-46%
P/E Ratio0.91N/A-
Revenue3.26M2.56M127%
Total Cash44.8M6.07M738%
Total Debt2.39M6.6M36%
FUNDAMENTALS RATINGS
SCYX vs TXMD: Fundamental Ratings
SCYX
TXMD
OUTLOOK RATING
1..100
8924
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9792
PRICE GROWTH RATING
1..100
4162
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
846

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TXMD's Valuation (41) in the Pharmaceuticals Generic industry is in the same range as SCYX (45) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew similarly to SCYX’s over the last 12 months.

TXMD's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as SCYX (100) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew similarly to SCYX’s over the last 12 months.

TXMD's SMR Rating (92) in the Pharmaceuticals Generic industry is in the same range as SCYX (97) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew similarly to SCYX’s over the last 12 months.

SCYX's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as TXMD (62) in the Pharmaceuticals Generic industry. This means that SCYX’s stock grew similarly to TXMD’s over the last 12 months.

SCYX's P/E Growth Rating (98) in the Pharmaceuticals Other industry is in the same range as TXMD (100) in the Pharmaceuticals Generic industry. This means that SCYX’s stock grew similarly to TXMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCYXTXMD
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 10 days ago
69%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
71%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TXMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AXP341.681.50
+0.44%
American Express Company
HOPE10.880.04
+0.37%
Hope Bancorp
IBP249.180.48
+0.19%
Installed Building Products
ZYXI1.45-0.02
-1.36%
Zynex
ARQ7.16-0.24
-3.24%
Arq

SCYX and

Correlation & Price change

A.I.dvisor tells us that SCYX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
-0.46%
ELAN - SCYX
32%
Poorly correlated
+3.65%
AKAN - SCYX
31%
Poorly correlated
+2.37%
SIGA - SCYX
28%
Poorly correlated
+4.33%
DRRX - SCYX
27%
Poorly correlated
N/A
CRDL - SCYX
26%
Poorly correlated
N/A
More

TXMD and

Correlation & Price change

A.I.dvisor tells us that TXMD and ASRT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TXMD and ASRT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TXMD
1D Price
Change %
TXMD100%
+0.94%
ASRT - TXMD
27%
Poorly correlated
-4.33%
TLRY - TXMD
24%
Poorly correlated
-3.36%
RMTI - TXMD
22%
Poorly correlated
+4.10%
TLPH - TXMD
22%
Poorly correlated
+0.48%
SCYX - TXMD
22%
Poorly correlated
-0.46%
More